MTD vs TRMB Stock Comparison: AI Score, Valuation, Performance and Upside
MTD (Mettler-Toledo) is the world's leading precision weighing instrument company with exceptional pharmaceutical and laboratory exposure and outstanding capital discipline, while TRMB (Trimble) provides precision GPS and workflow technology across construction, agriculture, and transportation verticals undergoing a software business model transition.
MTD vs TRMB compares two high-quality precision technology companies — Mettler-Toledo's world-leading analytical instruments with outstanding margins versus Trimble's positioning technology platform transitioning from hardware to software.
MTD holds the edge across 3 of 5 key metrics in this comparison. MTD has delivered stronger 1-year price return (-0.50% vs -31.49%), though TRMB trades at the lower forward P/E (12.37x vs 22.07x). On fundamentals, TRMB is growing revenue faster (11.80%), while MTD maintains the higher operating margin (23.29%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for TRMB (+69.25%) than for MTD (+17.35%).
- →Want the world's highest-quality precision weighing and analytical instrument company with pharmaceutical and laboratory market leadership
- →Value Mettler-Toledo's exceptional capital discipline and consistent earnings growth through focused buybacks
- →Prefer a stable, mature precision instrument business with high margins over a business model transformation story
- →Want exposure to precision GPS and workflow technology across construction, agriculture, and transportation
- →See Trimble's software ARR transition as creating higher-quality, more predictable recurring revenues over time
- →Value Trimble's positioning technology as mission-critical infrastructure for the construction industry's digital transformation
| Metric | MTD | TRMB |
|---|---|---|
| AI score | 49.8 | 37.9 |
| AI rank | #490 | #1334 |
| Latest close | $1,144.84 | $49.16 |
| 1M return | +8.95% | -9.90% |
| 6M return | -17.32% | -37.69% |
| 1Y return | -0.50% | -31.49% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | MTD | TRMB |
|---|---|---|
| 1Y ago | $9.99K (-0.1%) started 2025-06-18 | $6.86K (-31.4%) started 2025-06-18 |
| 5Y ago | $8.39K (-16.1%) started 2021-06-21 | $6.23K (-37.7%) started 2021-06-21 |
| 10Y ago | $30.45K (+204.5%) started 2016-06-20 | $18.41K (+84.1%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
| Metric | MTD | TRMB |
|---|---|---|
| Market cap | $22.86B | $11.75B |
| Trailing P/E | 26.60 | 26.40 |
| Forward P/E | 22.07 | 12.37 |
| Price/Sales | N/A | 4.83 |
| EV/Revenue | 6.12 | 3.51 |
| Analyst target | $1,327.83 | $85.33 |
| Target upside | +17.35% | +69.25% |
| Metric | MTD | TRMB |
|---|---|---|
| Revenue growth | 7.20% | 11.80% |
| Earnings growth | 6.70% | 55.60% |
| EPS growth | +6.70% | +55.60% |
| FCF margin | +15.04% | +10.04% |
| Operating margin | 23.29% | 15.87% |
| Profit margin | 21.40% | 12.38% |
| ROIC proxy | N/A | 8.25% |
| Return on equity | N/A | 8.25% |
| Dividend yield | N/A | N/A |
| Beta | 1.26 | 1.37 |
| Debt/equity | N/A | 25.06 |
| Current ratio | 1.20 | 1.01 |
| Quick ratio | 0.69 | 0.62 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | MTD | TRMB |
|---|---|---|---|
| 1Y | Growth | -0.05% | -31.44% |
| CAGR | -0.06% | -31.47% | |
| Sharpe ratio | 0.02 | -1.30 | |
| Max drawdown | 31.90% | 42.67% | |
| Max daily drop | 14.77% | 7.24% | |
| Max wkly drop | 22.72% | 17.35% | |
| 5Y | Growth | -16.10% | -37.74% |
| CAGR | -3.46% | -9.06% | |
| Sharpe ratio | -0.09 | -0.26 | |
| Max drawdown | 43.47% | 57.35% | |
| Max daily drop | 14.77% | 13.09% | |
| Max wkly drop | 22.72% | 17.35% | |
| 10Y | Growth | +204.49% | +84.12% |
| CAGR | +11.79% | +6.30% | |
| Sharpe ratio | 0.37 | 0.22 | |
| Max drawdown | 43.47% | 57.35% | |
| Max daily drop | 14.77% | 18.60% | |
| Max wkly drop | 22.72% | 38.07% |
| Category | MTD | TRMB |
|---|---|---|
| Company | Mettler-Toledo International Inc. | Trimble Inc. |
| Sector | Healthcare | Technology |
| Industry | N/A | Scientific & Technical Instruments |
| Core business | Mettler-Toledo is the world's largest supplier of precision weighing instruments and analytical systems for laboratory, industrial, and retail applications, with service and consumables generating significant recurring revenue alongside instrument sales. | Trimble provides precision positioning and workflow technology solutions for construction, geospatial, agriculture, and transportation industries, integrating GPS, sensors, software, and connectivity to improve productivity and efficiency in field operations. |
| Investor focus | Investors track Mettler-Toledo's organic revenue growth across laboratory, pharmaceutical, and industrial segments, service revenue growth, EBITDA margins consistently above 30%, and capital allocation through buybacks. | Investors track Trimble's Annual Recurring Revenue (ARR) growth as it transforms from hardware-heavy to software and subscription-centric, Connect & Scale 2025 strategy milestones, and profitability as the software mix increases. |
- →World's leading precision balance and analytical instrument company with unmatched product quality and customer trust in laboratory and pharmaceutical settings
- →High service revenue recurring component from instrument calibration, maintenance contracts, and laboratory consumables
- →Exceptional capital discipline — consistent buybacks reduce share count and drive EPS growth even through mid-single-digit revenue growth periods
- →Precision GPS and positioning technology is mission-critical for construction machine control, land surveying, and precision agriculture
- →Software and subscription transformation (Connect & Scale) is shifting revenue toward higher-margin, more predictable ARR
- →Transportation and agriculture precision management software creates high-switching-cost customer relationships
- →Pharmaceutical and laboratory instrument demand is sensitive to R&D spending cycles at pharmaceutical companies
- →China sales represent a significant portion of revenue and have been impacted by Chinese economic conditions and policy shifts
- →Premium pricing position faces sensitivity in weaker demand environments where customers delay non-critical instrument upgrades
- →Construction market cycles significantly affect Trimble's hardware revenues from machine control systems
- →Agricultural equipment demand volatility (tied to crop prices and farmer income) affects Trimble's precision agriculture hardware
- →Software transition creates near-term revenue headwinds as one-time hardware sales shift to recurring subscription models
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.